Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model

Markus Scholz1, Manuela Ackermann2, Frank Emmrich2, Markus Loeffler1, Manja Kamprad21Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Haertelstrasse 16&ndash;18, 04107 Leipzig, Germany; 2Institute for Clinical Immunology and Transfusion Medicine, Univers...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Markus Scholz, Manuela Ackermann, Frank Emmrich, Markus Loeffler, Manja Kamprad
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/1facb487237a4d2da691d8d1eaeea656
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1facb487237a4d2da691d8d1eaeea656
record_format	dspace
spelling	oai:doaj.org-article:1facb487237a4d2da691d8d1eaeea6562021-12-02T00:35:49ZEffectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model1177-54751177-5491https://doaj.org/article/1facb487237a4d2da691d8d1eaeea6562008-12-01T00:00:00Zhttp://www.dovepress.com/effectiveness-of-cytopenia-prophylaxis-for-different-filgrastim-and-pe-a2735https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Markus Scholz1, Manuela Ackermann2, Frank Emmrich2, Markus Loeffler1, Manja Kamprad21Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Haertelstrasse 16&ndash;18, 04107 Leipzig, Germany; 2Institute for Clinical Immunology and Transfusion Medicine, University of Leipzig, Johannisallee 30, 04103 Leipzig, GermanyObjectives: Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is widely used to treat neutropenia during cytotoxic chemotherapy. The optimal scheduling of rhG-CSF is unknown and can hardly be tested in clinical studies due to numerous therapy parameters affecting outcome (chemotherapeutic regimen, rhG-CSF schedules, individual covariables). Motivated by biomathematical model simulations, we aim to investigate different rhG-CSF schedules in a preclinical chemotherapy mouse model.Methods: The time course of hematotoxicity was studied in CD-1 mice after cyclophosphamide (CP) administration. Filgrastim was applied concomitantly in a 2 &times; 3-factorial design of two dosing options (2 &times; 20 &mu;g and 4 &times; 10 &mu;g) and three timing options (directly, one, and two days after CP). Alternatively, a single dose of 40 &mu;g pegfilgrastim was applied at the three timing options. The resulting cytopenia was compared among the schedules.Results: Dosing and timing had a significant influence on the effectiveness of filgrastim schedules whereas for pegfilgrastim the timing effect was irrelevant. The best filgrastim and pegfilgrastim schedules exhibited equivalent toxicity. Monocytes dynamics performed analogously to granulocytes. All schedules showed roughly the same lymphotoxicity.Conclusion: We conclude that effectiveness of filgrastim application depends heavily on its scheduling during chemotherapy. There is an optimum of timing. Dose splitting is better than concentrated applications. Effectiveness of pegfilgrastim is less dependent on timing.Keywords: rhG-CSF, chemotherapy toxicity, mice, cyclophosphamide, cytopenia, neutropenia Markus ScholzManuela AckermannFrank EmmrichMarkus LoefflerManja KampradDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2009, Iss default, Pp 27-37 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Markus Scholz Manuela Ackermann Frank Emmrich Markus Loeffler Manja Kamprad Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model
description	Markus Scholz1, Manuela Ackermann2, Frank Emmrich2, Markus Loeffler1, Manja Kamprad21Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Haertelstrasse 16&ndash;18, 04107 Leipzig, Germany; 2Institute for Clinical Immunology and Transfusion Medicine, University of Leipzig, Johannisallee 30, 04103 Leipzig, GermanyObjectives: Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is widely used to treat neutropenia during cytotoxic chemotherapy. The optimal scheduling of rhG-CSF is unknown and can hardly be tested in clinical studies due to numerous therapy parameters affecting outcome (chemotherapeutic regimen, rhG-CSF schedules, individual covariables). Motivated by biomathematical model simulations, we aim to investigate different rhG-CSF schedules in a preclinical chemotherapy mouse model.Methods: The time course of hematotoxicity was studied in CD-1 mice after cyclophosphamide (CP) administration. Filgrastim was applied concomitantly in a 2 &times; 3-factorial design of two dosing options (2 &times; 20 &mu;g and 4 &times; 10 &mu;g) and three timing options (directly, one, and two days after CP). Alternatively, a single dose of 40 &mu;g pegfilgrastim was applied at the three timing options. The resulting cytopenia was compared among the schedules.Results: Dosing and timing had a significant influence on the effectiveness of filgrastim schedules whereas for pegfilgrastim the timing effect was irrelevant. The best filgrastim and pegfilgrastim schedules exhibited equivalent toxicity. Monocytes dynamics performed analogously to granulocytes. All schedules showed roughly the same lymphotoxicity.Conclusion: We conclude that effectiveness of filgrastim application depends heavily on its scheduling during chemotherapy. There is an optimum of timing. Dose splitting is better than concentrated applications. Effectiveness of pegfilgrastim is less dependent on timing.Keywords: rhG-CSF, chemotherapy toxicity, mice, cyclophosphamide, cytopenia, neutropenia
format	article
author	Markus Scholz Manuela Ackermann Frank Emmrich Markus Loeffler Manja Kamprad
author_facet	Markus Scholz Manuela Ackermann Frank Emmrich Markus Loeffler Manja Kamprad
author_sort	Markus Scholz
title	Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model
title_short	Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model
title_full	Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model
title_fullStr	Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model
title_full_unstemmed	Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model
title_sort	effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/1facb487237a4d2da691d8d1eaeea656
work_keys_str_mv	AT markusscholz effectivenessofcytopeniaprophylaxisfordifferentfilgrastimandpegfilgrastimschedulesinachemotherapymousemodel AT manuelaackermann effectivenessofcytopeniaprophylaxisfordifferentfilgrastimandpegfilgrastimschedulesinachemotherapymousemodel AT frankemmrich effectivenessofcytopeniaprophylaxisfordifferentfilgrastimandpegfilgrastimschedulesinachemotherapymousemodel AT markusloeffler effectivenessofcytopeniaprophylaxisfordifferentfilgrastimandpegfilgrastimschedulesinachemotherapymousemodel AT manjakamprad effectivenessofcytopeniaprophylaxisfordifferentfilgrastimandpegfilgrastimschedulesinachemotherapymousemodel
_version_	1718403602303680512

Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model

Ejemplares similares